Target intelligence / Profile preview

Tumor protein p53 gene (TP53)

Target
TP53
Molecular classification
Transcription factor, Tumor suppressor gene
01

Overview

The **Tumor protein p53 gene (TP53)** encodes p53, a pivotal transcription factor and tumor suppressor protein that controls cell cycle progression, DNA repair, apoptosis, and maintenance of genomic stability. It is nicknamed the "guardian of the genome" because of its crucial role in protecting cells from genetic damage and tumorigenesis. TP53 is the most commonly mutated gene in human cancer, with alterations found in over half of all tumors. Mutations (either inherited or acquired) compromise its tumor suppressor activity, resulting in uncontrolled cell proliferation and increased cancer risk, most notably in Li-Fraumeni syndrome. Its protein product regulates numerous downstream targets and interacts with many cellular proteins to mediate stress responses, making it a cornerstone of cancer biology and a major focus for therapeutic targeting.

Other names
p53 geneTP53tumor protein p53 genecellular tumor antigen p53transformation-related protein 53 (TRP53)P53 tumor suppressorphosphoprotein p53antigen NY-CO-13
02

Mechanism of action

Restoration of wild-type p53 function (mutant reactivation); MDM2 inhibition (to enhance p53 activity); Exploitation of p53 pathway for apoptosis induction; Selective toxicity for p53-deficient cells; Modulation of cell cycle arrest.

03

Biological functions

Regulation of cell cycleInduction of apoptosis (programmed cell death)DNA repairGenomic stabilityResponse to cellular stressInhibition of cell proliferation
04

Disease associations

Cancer (driver of tumor development when mutated; involved in most human malignancies)Li-Fraumeni syndrome (hereditary cancer predisposition)Other roles in tumor progression, resistance to therapy, and disease prognosis
05

Safety considerations

Toxicity from excessive restoration or activation of p53 may cause off-target cell death or tissue damage.Tumor resistance due to TP53 mutation limits drug efficacy.Genetic testing for TP53 may have implications for family members due to hereditary cancer syndromes.
06

Interacting drugs

APR-246 (Eprenetapopt)

3 more in the full profile.

07

Biomarkers

TP53 mutation status (predicts therapy response/prognosis)p53 protein expression levels (IHC)Genomic instability indicatorsLi-Fraumeni syndrome genetic screening

Beyond the preview

Go deeper on Tumor protein p53 gene (TP53).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor protein p53 gene (TP53).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call